They’re eyeing the cattle outbreak, viral genetic changes and federal actions

BMI labels some people as having a disease, even if their excess body fat isn’t causing harm

A Louisiana man who died with H5N1 contracted it from a backyard flock and wild birds

The results show AI could streamline the cancer screening process

The memory center contains sparse but robust nerve cell connections

Two genetic analyses clarify when Neandertal genes infiltrated Homo sapiens DNA

The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.

When Larry Einhorn was a young physician in the early 1970s, actinomycin-D was the standard drug used to treat testicular cancer.

Regulators and health systems must adapt

A mathematical puzzle fascinated Susan Ellenberg as a child.

Phase III trial finds improved PFS, side effects with nivolumab+chemo

Mesa, Carvajal-Carmona, Cruz-Correa, Perez, Ramirez, Sanchez: “We’re here to help lead and collaborate.”

On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.

Obstacles to progress include systemic disparities and dwindling appropriations

Mace Rothenberg has stayed busy since stepping down as Pfizer’s chief medical officer in 2021 by pivoting to an ambitious endeavor in science communication: the Museum of Medicine and Biomedical Discovery.

Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Something odd turned up in one of Lawrence Phillips’s routine health screenings in 2008.

What will happen to biomedical research and health care in the aftermath of the 2024 election? The differences in outcomes couldn’t be more stark.